Introduction
============

Atrial fibrillation (AF), characterized by rapid chaotic oscillations of atria, is the most common sustained cardiac arrhythmia globally, and it is associated with a substantially increased risk of cerebral stroke, congestive heart failure, and demise [@B1]-[@B4]. The prevalence of AF is estimated to be approximately 1% in the general population, and it markedly increases as the population ages, occurring in nearly 10% of individuals over 80 years of age [@B1],[@B5]. There are more than 33 million people affected with AF worldwide in 2010, and this number is anticipated to increase steadily over the next several decades due to advancing ages [@B6],[@B7]. AF confers a five-fold increased risk for the incidence of stroke and a two-fold increased risk for heart failure, hence is rapidly becoming a heavy societal and monetary burden in the world [@B1]. Despite significant clinical importance, the defined etiology and pathogenesis of AF in an overwhelming majority of patients remain incompletely understood.

Previous studies have substantiated that AF is associated with both environmental and genetic risk factors [@B7]-[@B10]. The environmental risk factors are numerous, including advanced age, obesity, hypertension, concomitant cardiac diseases and even chronic inflammation and tumor [@B7],[@B10]-[@B12]. However, aggregating compelling evidence has demonstrated that genetic defects play a crucial role in the pathogenesis of AF, and mutations in a wide range of genes have been causally linked to AF, encompassing those coding for ion channels and their accessory subunits, gap junction channels, signaling molecules, and transcription factors among others [@B7]-[@B10],[@B12]-[@B28]. Nevertheless, given that the above-mentioned genetic mutations occur in low prevalence in patients with AF, it is justifiable to make a hypothesis that additional disease-causing genes are still to be identified.

As another member of the homeodomain-containing transcription factors, SHOX2 has been shown to be pivotal for normal cardiac development, especially for the development of the sinoatrial node, the primary cardiac pacemaker [@B29]-[@B32]. In mice, homozygous deletion of *Shox2* led to embryonic lethality between embryonic day 11.5 and embryonic day 13.5, due to severe cardiovascular defects, including bradycardia and hypoplastic sinoatrial node and sinus valves, and the aberrant expression of *Cx40* and *Cx43* as well as *Nkx2-5*, which were previously associated with AF [@B33]-[@B35], was verified in vivo specifically within the sinoatrial nodal region [@B30]. Additionally, in zebrafish embryos, knockdown of *Shox2* also caused severe bradycardia [@B30]. Moreover, a common *Shox2*-dependent genetic program has been demonstrated to prime the pacemaker cells in the pulmonary vein myocardium, creating a vulnerable substrate for AF [@B36]. Furthermore, clinical studies and animal experiments have established a pathogenic link between sinus node dysfunction and AF [@B37]. These findings make it warranted to screen *SHOX2* as a prime candidate gene for human AF.

Materials and Methods
=====================

Study participants
------------------

Between January 2015 and May 2017, a cohort of 162 unrelated patients with familial AF was recruited from the Chinese Han population. The available family members of the index patient harboring an identified *SHOX2* mutation were also included in this study. A total of 238 unrelated healthy individuals without AF, who were matched for ethnicity, age and gender, were enlisted as controls. The study participants experienced a comprehensive clinical investigation, including individual and familial history, detailed physical examination, standard 12-lead electrocardiogram and cardiac echocardiography as well as review of medical records. Diagnosis and classification of AF was made as previously described [@B14]. Subjects with hypertension, coronary heart disease, valvular heart disease, congenital heart disease, congestive heart failure, metabolic disorders, or any other recognized risk factor of AF were excluded from the study. The investigation was conducted in conformity with the ethical standards of the Declaration of Helsinki set forth in 1975. The study protocol was approved by the local Institutional Ethical Committee. Peripheral venous blood samples were drawn from the study participants after they gave informed consents. By using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), genomic deoxyribonucleic acid (DNA) was isolated from blood leukocytes.

Sequence analysis of *SHOX2*
----------------------------

In this investigation, the longest transcript (transcript 1) of *SHOX2* including a primate specific exon 2 (NM_003030.4), which encodes the longest isoform (b), was analyzed. Direct polymerase chain reaction (PCR)-sequencing of the coding exons and flanking introns as well as partial 5\'- and 3\'-untranslated regions of *SHOX2* was performed in all study participants, as described previously [@B38]-[@B41]. The primer pairs used for amplification of *SHOX2* are listed in Table [1](#T1){ref-type="table"}. The primers were designed using genomic DNA sequences of *SHOX2* from GenBank (<https://www.ncbi.nlm.nih.gov/nuccore/NG_047079.1?from=5040&to=15192&report=genbank>), with an accession number of NG_047079.1. For an identified sequence variation, a repeated PCR-sequencing was performed to verify it. In addition, the identified sequence variation was queried in the single nucleotide polymorphism (SNP) database (<https://ncbi.nlm.nih.gov/projects/SNP>), the Human Gene Mutation (HGM) database (<http://www.hgmd.cf.ac.uk/ac/index.php>), the 1000 Genome Project (1000GP) database (<http://www.internationalgenome.org>), the Exome Aggregation Consortium (ExAC) database (<http://exac.broadinstitute.org/>), and the Exome Variant Server (EVS) database (<http://evs.gs.washington.edu/EVS>) to confirm its novelty.

Plasmid constructs and site-targeted mutagenesis
------------------------------------------------

The expression plasmid SHOX2-pcDNA3, which contains full-length cDNA of human *SHOX2* (NM_003030.4) as well as the reporter plasmids of bone morphogenetic protein 4-luciferase (BMP4-luc) and islet 1-luciferase (ISL1-luc) was constructed as described previously [@B42],[@B43]. The reporter plasmids of BMP4-luc and ISL1-luc both express Firefly luciferase. The mutation discovered in AF patients was introduced into the wild-type *SHOX2* by PCR with a complementary pair of primers using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, USA). The mutant-type SHOX2-pcDNA3 plasmid was selected by *Dpn*I (TaKaRa, Dalian, Liaoning, China) digestion and validated by direct sequencing.

Cellular transfection and luciferase assays
-------------------------------------------

Human embryonic kidney (HEK)-293 cells were grown at 37℃ in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal calf serum as well as 100 μg/ml streptomycin and 100 U/ml penicillin. Cells were cultured in 12-well plates 24 h before transient transfection. HEK-293 cells were transfected with 1.0 μg of wild-type or mutant SHOX2-pcDNA3, 1.0 μg of BMP4-luc and 0.04 μg of pGL4.75 (Promega, Madison, WI, USA) by using Lipofectamine^TM^ 3000 transfection reagent (Invitrogen, Carlsbad, California, USA). The plasmid pGL4.75, which expresses Renilla luciferase, was used as an internal control to normalize transfection efficiency. For co-transfection experiments, 0.5 μg of wild-type SHOX2-pcDNA3 together with 0.5 μg of mutant SHOX2-pcDNA3 or 0.5 μg of empty pcDNA3 plasmid was used in the presence of 1.0 μg of BMP4-luc and 0.04 μg of pGL4.75. For the analysis of the transcriptional activation of the *ISL1* promoter by SHOX2, the reporter plasmid ISL1-luc was used instead of BMP4-luc. The luciferase activity was measured 36 h after transfection with the Dual-Luciferase^®^ Reporter Assay System (Promega), according to the manufacturer\'s protocol. The activity of the *BMP4* or *ISL1* promoter was expressed as fold activation of Firefly luciferase relative to Renilla luciferase. Experiments were done independently at least three times in triplicate for either wild-type or mutant *SHOX2* with consistent results.

Statistics
----------

The baseline clinical characteristics of study participants were expressed as means ± standard deviations (SD) for continuous variables or counts and percentages for categorical variables. Participant\'s characteristics were compared between two groups with unpaired Student\'s *t* test or Mann-Whitney U statistic for continuous variables or chi-square or Fisher\'s exact test for categorical variables as appropriate. For luciferase assays, data are presented as means ± SD from three independent experiments in triplicate. Comparisons between experimental groups were made with unpaired Student\'s *t* test or one-way ANOVA, with a P value \< 0.05 indicated statistical difference. All statistics were performed using SAS (version 9.2; SAS Institute Inc., Cary, NC, USA).

Results
=======

Baseline clinical characteristics of the study population
---------------------------------------------------------

In the current study, 162 unrelated patients affected with AF were clinically evaluated in contrast to 238 unrelated individuals without AF. The study participants had no recognized environmental risk factors predisposing to AF, such as essential hypertension, coronary artery disease, valvular heart disease, previous cardiac surgery, chronic obstructive pulmonary disease and hyperthyroidism [@B1]. There is higher incidence of familial AF, ischemic stroke and implanted pacemaker, and a larger left atrial diameter in the patient group than in the control group. No significant difference in gender, age, or race existed between the two groups. The baseline clinical features of the 162 unrelated cases with AF are summarized in Table [2](#T2){ref-type="table"}.

Identification of a novel SHOX2 mutation
----------------------------------------

By sequencing all coding exons and flanking introns as well as parts of the 5\'- and 3\'-untranslated regions of the *SHOX2* gene, a heterozygous mutation was detected in an index patient suffered from AF. Specifically, a substitution of thymine for cytosine at nucleotide 580 (c.580C\>T), predicting to generate a truncated protein with only amino-terminal 193 amino acids (p.R194X), was identified in the proband from family 1. The DNA sequence electropherograms showing the detected heterozygous *SHOX2* mutation and its wild-type control sequence are displayed in Figure [1](#F1){ref-type="fig"}A. The schematic diagrams of SHOX2 proteins showing the homeobox domain and location of the mutation identified in this study are presented in Figure [1](#F1){ref-type="fig"}B. The nonsense mutation was neither discovered in 476 control chromosomes nor found in the SNP, HGM, 1000GP, ExAC and EVS databases, which were consulted again on April 29, 2018, indicating that it is a novel mutation.

A genetic screen of the proband′s family members available revealed that the same mutation was present in all affected family members, but absent in unaffected family members. Analysis of the pedigree showed that in the family AF was transmitted in an autosomal dominant pattern with complete penetrance. The pedigree structure of the family with AF is shown in Figure [1](#F1){ref-type="fig"}C. The phenotypic features and mutational status for *SHOX2* of the affected pedigree members are given in Table [3](#T3){ref-type="table"}.

Additionally, all the mutation carriers in this family had severely reduced heart rates (sinus bradycardia) and significantly prolonged PR interval as well as RR and QRS lengths prior to AF occurrence. There is no significant difference in corrected QT intervals between the affected individuals and the unaffected individuals. Besides, the affected individuals had shorter stature when compared to their healthy parents, but no obvious craniofacial or brain anomalies were observed.

No transcriptional activation of the *BMP4* promoter by R194X-mutant SHOX2
--------------------------------------------------------------------------

Previous studies have validated that SHOX2 transactivates the expression of BMP4 [@B42]. To ascertain whether the identified mutation exerts an impact on the transactivational activity of SHOX2, luciferase reporter assays were performed. Consistent with its role as a transcription factor, wild-type SHOX2 activated the promoter of its target gene *BMP4*, while the R194X-mutant SHOX2 failed to activate its target molecule. As shown in Figure [2](#F2){ref-type="fig"}, the wild-type and R194X-mutant SHOX2 proteins activated the *BMP4* promoter by \~16 folds and \~1 fold, respectively. When the wild-type and R194X-mutant SHOX2 proteins were co-expressed, the induced activation of the *BMP4* promoter was \~7-fold, indicating that the R194X-mutant SHOX2 protein fails to transactivate the *BMP4* promoter compared with its wild-type counterpart.

Failure to transactivate the *ISL1* promoter by R194X-mutant SHOX2
------------------------------------------------------------------

Previous investigations have substantiated that *ISL1* is a direct transcriptional target of SHOX2 [@B43]. To evaluate the functional consequence of the found nonsense mutation, luciferase reporter analyses of wild-type SHOX2 and R194X-mutant SHOX2 were performed. As expected, wild-type SHOX2 transcriptionally activated the promoter of its target gene *ISL1*, while the R194X-mutant SHOX2 was not able to activate its target. As shown in Figure [3](#F3){ref-type="fig"}, the wild-type and R194X-mutant SHOX2 proteins activated the *ISL1* promoter by \~6 folds and \~1 fold, respectively. When the wild-type and R194X-mutant SHOX2 proteins were co-expressed, the induced activation of the *ISL1* promoter was \~3-fold, indicating that the R194X-mutant SHOX2 protein has no transcriptional activation of the *ISL1* promoter.

Discussion
==========

In the present study, a novel heterozygous nonsense mutation in SHOX2, p.R194X, was identified in a family with AF. The mutation co-segregated with AF in the family and was absent from the 476 reference chromosomes. The nonsense mutation was predicted to create a truncated protein with only half homeobox left. The homeobox domain is responsible for target DNA sequence recognition and binding to the consensus motif, hence is a functionally pivotal structural domain [@B44]. Functional analyses demonstrated that the mutant SHOX2 protein had no transcriptional activity. Therefore it is very likely that *SHOX2* loss-of-function mutation contributes to AF in mutation carriers.

In humans, *SHOX2* maps on chromosome 3q25.32, coding for three isoforms of proteins, encompassing isoform a (with 331 amino acids), isoform b (with 355 amino acids) and isoform c (with 319 amino acids). Previous studies have substantiated that SHOX2 transcriptionally regulates expression of many genes in the heart, including *HCN4*, *NKX2-5*, *CX40*, *CX43* and *NPPA* [@B44]. Furthermore, mutations in several target genes mediated by SHOX2 have been causally linked to AF [@B24],[@B33]-[@B35],[@B45]-[@B49]. In the present study, the functional characteristics of the novel *SHOX2* mutation identified in patients with familial AF were analyzed by dual-luciferase assays and the results indicated that the mutant SHOX2 protein failed to transcriptionally activate the *BMP4* or *ISL1* promoter. These observational results imply that *SHOX2* haploinsufficiency resulted from a mutation is potentially an alternative molecular mechanism of AF.

Association of genetically compromised *SHOX2* with increased susceptibility to AF may be partially attributed to abnormal development of the heart, especially the sinoatrial node. During embryonic cardiac development, SHOX2 is highly expressed in the sinus venosus region, including the sinoatrial nodes and the sinus valves [@B30],[@B31], and similar expression profile of SHOX2 was also observed in the human embryonic heart [@B29],[@B50]. In mice, homozygous deletion of *Shox2* resulted in embryonic lethality between embryonic days 11.5 and 13.5 due to cardiac defects, including severe hypoplasia of sinoatrial nodes and bradycardia associated with down-regulation of the sinoatrial node-specific marker genes, *Tbx3* and *Hcn4*, and ectopic expression of *Nkx2-5*, *Cx40*, *Cx43*, and *Nppa* within the sinoatrial node region [@B30],[@B31]. In mice with *Shox2* replaced by the closely related but hypomorphic *Shox* allele, embryonic lethality was rescued, but arrhythmias remained [@B50]. In zebrafish, targeted knockdown of *Shox2* using morpholino-modified antisense oligonucleotides led to pericardial edema and pericardial blood congestion because of severely reduced heart rates in zebrafish embryos, and the bradycardia in *Shox2* morphants could be rescued by cardiomyocyte-specific expression of wild-type SHOX2 [@B43]. Furthermore, gene expression analysis demonstrated that SHOX2 and NKX2-5 were expressed in a mutually exclusive manner from the earliest formation stages of the venous poles and sinoatrial nodes until at least embryonic day15.5 [@B30],[@B31], and overexpression of NKX2-5 caused the same sinoatrial node and sinus valve phenotypes as that observed in *Shox2*-mull hearts, indicating that NKX2-5 activity is detrimental to sinoatrial nodal development and that SHOX2 plays a key role in sinoatrial nodal development through repression of *Nkx2-5* [@B51]. Taken collectively, these findings suggest that a haploinsufficient mutation in *SHOX2* predisposes to arrhythmias, including AF.

Notably, *SHOX2* mutations were previously identified in patients with early-onset AF. Hoffmann and colleagues [@B52] made a sequence analysis of *SHOX2* in 378 unrelated patients with early-onset AF, and identified two heterozygous mutations (p.G81E and p.H283Q) in two patients, respectively. Transactivation studies of the identified two missense mutations with two known SHOX2 target genes *BMP4* and *ISL1* unveiled that the p.G81E mutation had no effect on the transcriptional activity of SHOX2, while the p.H283Q mutation failed to activate both *BMP4* and *ISL1* target genes [@B52]. Further functional analysis in the zebrafish displayed that the p.H283Q mutation severely impaired cardiac pacemaker function. The same authors also demonstrated significantly reduced expression levels of SHOX2 in right atrial appendages of AF patients compared to patients with sinus rhythm [@B52]. These results together with the current study suggest that mutated *SHOX2* may be a rare cause for AF.

In conclusion, the present research firstly associates a *SHOX2* loss-of-function mutation with enhanced susceptibility to familial AF in humans, which provides novel insight into the molecular pathogenesis underpinning AF, suggesting potential implications for genetic counseling and personalized treatment of the patients with AF.
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![A novel *SHOX2* mutation associated with familial atrial fibrillation. (**A**) Sequence chromatograms displaying the heterozygous *SHOX2* mutation and its homozygous wild-type control. The *arrow* points to the homozygous nucleotides of C/C in a healthy subject (wild type) or the heterozygous nucleotides of C/T in the proband (mutant). The rectangle denotes the nucleotides constituting a codon of *SHOX2*. (**B**) Schematic diagrams of human SHOX2 proteins. The truncated protein associated with atrial fibrillation was shown with half structural domain of homeobox. NH2, amino-terminus; COOH, carboxyl-terminus. (**C**) Pedigree structure of the family with atrial fibrillation. The family was arbitrarily designated as family 1. Family members are identified by generations and numbers. Squares indicate male family member; circles, female members; a symbol with a slash, the deceased member; closed symbols, affected members; open symbols, unaffected members; the arrow, the proband; "+", carriers of the heterozygous mutation; "-", non-carriers.](ijmsv15p1564g001){#F1}

![Failure to transcriptionally activate the *BMP* promoter by R194X-mutant SHOX2. Activation of the *BMP4*-driven luciferase in HEK-293 cells by wild-type or R194X-mutant SHOX2, alone or in combination, showed that the R194X-mutant SHOX2 protein failed to transcriptionally activate the *BMP4* promoter. Three independent experiments were carried out in triplicates. The data are expressed as means and standard deviations. \*\* indicates t = 11.3237, p = 0.00035; \* indicates t = 5.90352, p = 0.00412, when compared with wild-type *SHOX2*.](ijmsv15p1564g002){#F2}

![Inability to transcriptionally activate the *ISL1* promoter by R194X-mutant SHOX2. Activation of the *ISL1*-driven luciferase in HEK-293 cells by wild-type or R194X-mutant SHOX2, alone or in combination, showed that the R194X-mutant SHOX2 protein was unable to transcriptionally activate the *ISL1* promoter. Three independent experiments were carried out in triplicates. The data are given as means and standard deviations. \*\* indicates t = 7.94861, p = 0.00136; \* indicates t = 3.42684, p = 0.02661, when compared with wild-type *SHOX2*.](ijmsv15p1564g003){#F3}

###### 

Primers to amplify the coding exons and flanking introns of the *SHOX2* gene.

  -------------------------------------------------------------------------------------
  Coding exon   Forward primer (5´ to 3´)   Reverse primer (5´ to 3´)   Amplicon (bp)
  ------------- --------------------------- --------------------------- ---------------
  1\            TCTGCTGGCAGAGGTTGAGCG\      GACCGAGCATACCACCGGAC\       567\
  2             CCTCTAGCGCAGAGTTTGCC        CAGGCACCAAGTGCCAAATCAA      446

  3\            GCGGTGAGTCGAGGTACGTT\       CACCACCTCCCGAGTGTGTC\       577\
  4, 5\         TGCTGTATCTCCCAATTCTTGTCT\   TGGGCTCAGAGACAGGTGATGTT\    661\
  6             GTCGGAACAAGATGCACAGCC       TGCCTCGTGAGATCCCTGGT        608
  -------------------------------------------------------------------------------------

###### 

Baseline demographics and clinical features of the study population.

  Parameter                                   Patient group (n =162)   Control group (n =238)   *p*-value
  ------------------------------------------- ------------------------ ------------------------ --------------
  Age (years)                                 55.7 ± 9.3               56.4 ± 10.1              0.4828
  Gender (male/female)                        85/77                    125/113                  0.9919
  Family history of atrial fibrillation (%)   38 (23)                  0 (0)                    \<0.0001^\*^
  History of ischemic stroke (%)              7 (4)                    0 (0)                    0.0011^\*^
  History of implanted pacemaker (%)          5 (3)                    0 (0)                    0.0094^\*^
  Body mass index (kg/m^2^)                   23.5 ± 2.1               23.8 ± 2.4               0.1978
  Systolic blood pressure (mmHg)              128.4 ± 10.6             129.7 ± 12.3             0.2736
  Diastolic blood pressure (mmHg)             83.1 ± 7.2               82.7 ± 6.8               0.5732
  Fasting blood glucose (mmol/L)              4.6 ± 0.7                4.5 ± 0.6                0.1272
  Total cholesterol (mmol/L)                  3.7 ± 0.8                3.6 ± 0.6                0.1543
  Triglyceride (mmol/L)                       1.5 ± 0.5                1.5 ± 0.4                1.0000
  Left atrial diameter (mm)                   38.5 ± 8.1               36.2 ± 7.0               0.0026^\*^
  Left ventricular ejection fraction (%)      63.0 ± 8.5               63.7 ± 7.6               0.3894
  Resting heart rate (beats/min)              75.2 ± 18.5              74.8 ± 12.3              0.7952
  History of alcohol consumption (%)          15 (9)                   23 (10)                  0.8922
  History of smoking (%)                      12 (7)                   20 (8)                   0.7185

Data are expressed as mean with standard deviation for a continuous variable or number with percentage for a categorical variable.

^\*^ indicates significant difference between the two groups.

###### 

Phenotypic features and status of SHOX2 mutation of the affected living pedigree members.

  Subject information   Phenotype   Electrocardiogram              Echocardiogram                   Genotype                                                                                       
  --------------------- ----------- ------------------------------ -------------------------------- --------------------- ------------------------ ------------------- ----- ---------- ---------- ----------------
  Identity              Gender      Age at time of study (years)   Age at diagnosis of AF (years)   AF (Classification)   Heart rate (beats/min)   QRS interval (ms)   QTc   LAD (mm)   LVEF (%)   SHOX2 mutation
  Family 1                                                                                                                                                                                         R194X
  II-1                  M           53                             41                               Permanent             87                       100                 447   35         62         +/-
  II-6                  F           47                             43                               Permanent             62                       116                 528   38         60         +/-
  II-7                  M           45                             39                               Persistent            71                       102                 450   33         63         +/-
  III-1                 F           20                             20                               Paroxysmal            75                       96                  435   30         65         +/-

AF: atrial fibrillation, F: female, M: male, QTc: corrected QT interval, LAD: left atrial diameter, LVEF: left ventricular ejection fraction, +/-: heterozygote.
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